Printer Friendly

PERSEPTIVE BIOSYSTEMS, INC. LAUNCHES AUTOPILOT FOR PILOT-SCALE PURIFICATION WITH FIRST SYSTEM SALE

 CAMBRIDGE, Mass., Jan. 25 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ: PBIO) announced today that it has begun to sell its AutoPilot(tm) System for pilot-scale purification of biopharmaceuticals. AutoPilot combines validated control software with PerSeptive's unique approach to chromatographic software and hardware integration with the company's patented Perfusion Chromatography(R) technology. AutoPilot permits rapid scale-up of validated methods to kilogram-scale production of biopharmaceuticals.
 Noubar B. Afeyan, Ph.D., president and CEO of PerSeptive, stated: "With the introduction of the AutoPilot System, PerSeptive now has a full line of equipment and media for the biopharmaceutical purification challenge. Our customers can now develop and optimize their purification processes using new low-pressure POROS(R) 50 media and the BioCAD(tm) Workstation and then use the AutoPilot System for rapid scale-up to kilogram scale production of their drugs."
 The AutoPilot System operates at flow rates up to 10 liters per minute through a user-friendly, validated software system, and runs columns from 10 to 100 liters in size.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection(tm) and Rational Surface Design(tm).
 Perfusion Chromatography and POROS are registered trademarks and AutoPilot and BioCAD are trademarks of the company.
 -0- 1/25/93
 /CONTACT: Robert A. Fein, vice president and Chief financial officer, or Robert B. Anacone, senior vice president, marketing and sales, Perseptive Biosystems, Inc., 617-621-1787/
 (PBIO)


CO: PerSeptive Biosystems ST: Massachusetts IN: MTC SU: PRD

TM -- NE005 -- 8266 01/25/93 08:45 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 25, 1993
Words:292
Previous Article:RESULTS OF HUMAN PHASE I TRIAL OF CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT REPORTED
Next Article:INFORMATION MAPPING SIMPLIFIES ISO 9000 CERTIFICATION PROCESS; ISO 9000 MAPS SERIES TARGETS GROWING GLOBAL MARKETPLACE
Topics:


Related Articles
ROBERT B. ANACONE NAMED SENIOR VICE PRESIDENT, MARKETING AND SALES AT PERSEPTIVE BIOSYSTEMS
PERSEPTIVE BIOSYSTEMS ANNOUNCES THIRD QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS, INC. FILES REGISTRATION STATEMENT WITH SEC FOR PUBLIC OFFERING OF 2 MILLION SHARES OF COMMON STOCK
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES PUBLIC OFFERING OF TWO MILLION SHARES AT $18 PER SHARE
PERSEPTIVE BIOSYSTEMS ANNOUNCES ACQUISITION OF VESTEC CORPORATION
PERSEPTIVE BIOSYSTEMS REPORTS RESULTS FOR FIRST FISCAL QUARTER OF 1996
PERSEPTIVE BIOSYSTEMS INTEGRATES BIOMOLECULE PURIFICATION AND ANALYSIS IN NEW VISION(TM) WORKSTATION
PerSeptive Biosystems Announces New Perfusion Chromatography(R) Patent
PerSeptive Biosystems Announces Advances in Human Genome Analysis
PerSeptive Biosystems Appoints Hewlett-Packard Executive Don Schoeny Senior Vice President, Worldwide Sales, Service and Technical Support

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters